TP53 and cancer: Previous reports using adavosertib in combination with DNA-damaging chemotherapeutics or radiotherapy demonstrated p53-deficient cancer cells to be more susceptible to WEE1 inhibition [17–19]; such that TP53 mutation status has been cited as a biomarker of response in clinical studies of adavosertib [33].